Literature DB >> 378308

Anti-aggregatory effect of prostacyclin (PGI2) in vivo.

B L Bayer, K E Blass, W Förster.   

Abstract

Prostacyclin (PGI2) when infused intravenously reduced the mortality of rabbits given high intravenous doses of arachidonic acid (AA). Prostaglandins E1 and D2 were ineffective. Indomethacin pretreatment abolished the toxic AA effect. Since the lethal effect of AA is partly due to the formation of platelet aggregates it is concluded that PGI2 is a most potent anti-aggregatory prostaglandin in vivo.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 378308      PMCID： PMC2043836          DOI： 10.1111/j.1476-5381.1979.tb16090.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


  11 in total

1.  Arachidonic acid as a precursor in the production of substances necessary for platelet aggregation and its control.

Authors:  K C Srivastava
Journal:  Dan Med Bull       Date:  1978-04

2.  The effect of prostaglandin E1 on platelet function in vitro and in vivo.

Authors:  R L Kinlough-Rathbone; M A Packham; J F Mustard
Journal:  Br J Haematol       Date:  1970-11       Impact factor: 6.998

3.  Effect of prostaglandin E1 on platelet behaviour in vitro and in vivo.

Authors:  P R Emmons; J R Hampton; M J Harrison; A J Honour; J R Mitchell
Journal:  Br Med J       Date:  1967-05-20

4.  Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides.

Authors:  R J Gryglewski; S Bunting; S Moncada; R J Flower; J R Vane
Journal:  Prostaglandins       Date:  1976-11

5.  An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation.

Authors:  S Moncada; R Gryglewski; S Bunting; J R Vane
Journal:  Nature       Date:  1976-10-21       Impact factor: 49.962

6.  Modulation of human platelet adenylate cyclase by prostacyclin (PGX).

Authors:  R R Gorman; S Bunting; O V Miller
Journal:  Prostaglandins       Date:  1977-03

7.  Some actions of prostacyclin (PGI2) on the cardiovascular system and the gastric microcirculation.

Authors:  B J Whittle; S Moncada; J R Vane
Journal:  Acta Biol Med Ger       Date:  1978

8.  Arachidonic acid causes sudden death in rabbits.

Authors:  M J Silver; W Hoch; J J Kocsis; C M Ingerman; J B Smith
Journal:  Science       Date:  1974-03-15       Impact factor: 47.728

9.  Comparison of the vasodepressor effects of prostacyclin and 6-oxo-prostaglandin F1alpha with those of prostaglandin E2 in rats and rabbits.

Authors:  J M Armstrong; N Lattimer; S Moncada; J R Vane
Journal:  Br J Pharmacol       Date:  1978-01       Impact factor: 8.739

10.  Prostacyclin (PGI2) inhibits the formation of platelet thrombi induced by adenosine diphosphate (ADP) in vivo [proceedings].

Authors:  G A Higgs; S Moncada; J R Vane
Journal:  Br J Pharmacol       Date:  1977-09       Impact factor: 8.739
View more
  5 in total

Review 1.  Nobel lecture. Adventures and excursions in bioassay--the stepping stones to prostacyclin.

Authors:  J R Vane
Journal:  Postgrad Med J       Date:  1983-12       Impact factor: 2.401

Review 2.  Eighth Gaddum Memorial Lecture. University of London Institute of Education, December 1980. Biological importance of prostacyclin.

Authors:  S Moncada
Journal:  Br J Pharmacol       Date:  1982-05       Impact factor: 8.739

3.  Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial.

Authors:  A H Gershlick; D Spriggins; S W Davies; Y D Syndercombe Court; J Timmins; A D Timmis; M T Rothman; C Layton; R Balcon
Journal:  Br Heart J       Date:  1994-01

4.  Epoprostenol sodium (prostacyclin) infusion in acute myocardial infarction.

Authors:  F J Kiernan; J Kluger; J C Regnier; M Rutkowski; A Fieldman
Journal:  Br Heart J       Date:  1986-11

Review 5.  Cell detachment and metastasis.

Authors:  L Weiss; P M Ward
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.